Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: Implications for imatinib mesylate response and resistance

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1651-1664

  Kurzrock, Razelle ^a   Talpaz, Moshe ^a   Li, Lan ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bcr Abl; Imatinib mesylate; Kinase; Leukemia; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

BLAST CRISIS; CELL LINE; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33748541956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600709572     Document Type: Article

References (29)

1. Druker, B and Talpaz, M and Resta, D and Peng, B and Buchdunger, E and Ford, J and (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med, 344, pp. 1031-1037.
2. Druker, B and Sawyers, C and Kantarjian, H and Resta, D and Reese, S and Ford, J and (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med, 344, pp. 1038-1042.
3. Sawyers, C and Hochhaus, A and Feldman, E and Goldman, J and Miller, C and Ottmann, O and (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study Blood, 99, pp. 3530-3539.
4. Shah, N and Nicoll, J and Nagar, B and Gorre, M and Paquette, R and Kuriyan, J and (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell, 2, pp. 117-125.
5. Hochhaus, A and Kreil, S and Corbin, A and LaRosee, P and Muller, M and Lahaye, T and (2002) Molecular and chromosomal mechanisms of resistance to imatinib (571) therapy Leukemia, 6, pp. 2190-2196.
6. Lozzio, B and Lozzio, C. (1979) Properties and usefulness of the original K562 human myelogenous leukemia cell line Leukemia Res, 3, pp. 363-370.
7. Dean, A and Erard, F and Schneider, A and Schechter, A. (1981) Induction of hemoglobin accumulation in human K562 cells by hemin is reversible Science, 212, pp. 459-461.
8. Eisbruch, A and Blick, M and Evinger-Hodges, M and Beran, M and Andersson, B and Gutterman, J and (1988) Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line Cancer, 62, pp. 1171-1178.
9. Avanzi, G and Lista, P and Giovinazzo, B and Miniero, R and Saglio, G and Benetton, G and (1988) Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features Br J Haematol, 69, pp. 359-366.
10. Faderl, S and Estrov, Z and Kantarjian, H and Harris, D and Van, Q and Fokt, I and (2001) WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity Anticancer Res, 21, pp. 3777-3784.
11. Estrov, Z and Manna, S and Harris, D and Van, Q and Estey, E and Kantarjian, H and (1999) Phenylarsine oxide blocks Interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells Blood, 94, pp. 2844-2853.
12. Sirard, C and Laneuville, P and Dick, J. (1994) Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanism Blood, 83, pp. 1575-1585.
13. Laurent, E and Talpaz and Kantarjian, H and Kurzrock. (2001) The BCR gene and Philadelphia-positive leukemogenesis Cancer Res, 61, pp. 2343-2355.
14. Goldman, J. (2002) CML yields a few more clues Blood, 99, pp. 3491.
15. Buchdunger, E and Zimmermann, J and Mett, H and Meyer, T and Muller, M and Druker, B and (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res, 56, pp. 100-104.
16. Gorre, M and Mohammed, M and Ellwood, K and Hsu, N and Paquette, R and Rao, P and (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science, 293, pp. 876-880.
17. LeCoutre, P and Tassi, E and Varella-Garcia, M and Barni, R and Mologni, L and Cabrita, G and (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood, 95, pp. 1758-1766.
18. Weisberg, E and Griffin, J. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood, 95, pp. 3498-3505.
19. Mahon, F and Deininger, M and Schultheis, B and Chabrol, J and Reiffers, J and Goldman, J and (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance Blood, 96, pp. 1070-1079.
20. von Bubnoff, N and Schneller, F and Peschel, C and Duyster, J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: A prospective study Lancet, 359, pp. 487-491.
21. Gambacorti-Passerini, C and Barni, R and le Coutre, P and Zucchetti, M and Cabrita, G and Cleris, L and (2000) Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemic cells to the Abl inhibitor STI571 J Natl Cancer Inst, 92, pp. 1641-1650.
22. Jorgensen, H and Elliott, M and Allan, E and Carr, C and Holyoake, T and Smith, K. (2000) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571 Blood, 99, pp. 713-715.
23. Donato, N and Wu, J and Stapley, J and Liu, H and Arlinghaus, R and Aggarwal, B and Shishodin, S and (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia Cancer Res, 64, pp. 672-677.
24. Sun, X and Layton, J and Elefanty, A and Lieschke, G. (2001) Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571 Blood, 97, pp. 2008-2015.
25. Druker, B and Tamura, S and Buchdunger, E and Ohno, S and Segal, G and Fanning, S and (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med, 2, pp. 561-566.
26. Pierce, A and Owen-Lynch, P and Spooncer, E and Dexter, T and Whetton, A. (1998) P210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia Oncogene, 17, pp. 667-672.
27. Donato, N and Wu, J and Zhang, L and Kantarjian, H and Talpaz, M. (2001) Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL human leukemic cells: Association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition Blood, 97, pp. 2846-2853.
28. Mukhopadhyay, A and Shishodia, S and Suttles, J and Brittingham, K and Lamothe, B and Nimmanapalli, R and (2002) Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-κB activation and IκBα phosphorylation J Biol Chem, 41, pp. 38159-38167.
29. Mayerhofer, M and Florian, S and Krauth, M and Aichberger, K and Bilban, M and Marculescu, R and (2004) Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia Cancer Res, 64, pp. 3148-3154.